Loading
A phase 2 trial of Fluoroestradiol F-18 and Fludeoxyglucose F-18 in Breast cancer, run by University of Washington, active and no longer recruiting.
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy is a phase 2 interventional study registered as NCT04692103 by University of Washington, with 2 participants planned, started 2021-07-10 and due to reach its primary completion in 2021-10-01. Interventions recorded: F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Laboratory Biomarker Analysis. Conditions recorded: Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7.
Linked to the drug Fludeoxyglucose F-18 because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
2 enrolled.
range 77 to 79; Figures from the ClinicalTrials.gov results section (first posted 2023-02-21), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV) - Avg SULmaxprimary | Diagnostic (F-18 FES PET/CT) | 2 | 78% | - | - | link |
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares Fludeoxyglucose F-18 (FDG) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.